Solid Biosciences INC 8-K filings

Solid Biosciences has filed a prospectus supplement to its universal shelf registration statement, enabling the offer and sale of up to $200.0 million of its common stock.

Solid Biosciences Inc. held its Annual Meeting of Stockholders on June 10, 2026, where shareholders elected directors, ratified auditor appointments, and approved a significant increase in authorized common stock.

Solid Biosciences Inc. announced a strategic realignment of its Board of Directors to ensure balanced class membership, with Ilan Ganot transitioning to a new directorship.

Solid Biosciences Inc. announced a private placement raising $240 million, extending its cash runway into the first half of 2028.

Solid Biosciences announced positive interim data from its INSPIRE DUCHENNE trial, Q3 2025 financial results, and an extended cash runway into H1 2027.

Solid Biosciences Inc. announced that its stockholders approved a significant increase in authorized common stock and an amendment to its equity incentive plan, alongside the election of directors and ratification of auditors at its Annual Meeting.

Solid Biosciences has filed a prospectus supplement to offer and sell up to $85 million of its common stock.

Solid Biosciences has announced a $200 million underwritten offering of common stock and pre-funded warrants to fund its genetic medicine pipeline.

Solid Biosciences has announced a $200 million underwritten offering expected to close on February 19, 2025, to fund operations into the first half of 2027.

Solid Biosciences reports promising early data from its Phase 1/2 INSPIRE DUCHENNE trial, showcasing significant microdystrophin expression and improvements in muscle health biomarkers with SGT-003.

Solid Biosciences reports the resignation of two board members, approval of a share increase, and an amendment to their equity incentive plan at their annual meeting.